Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: schuster mw. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Peters WP, et al. Among authors: schuster mw. J Clin Oncol. 2005 Apr 1;23(10):2191-200. doi: 10.1200/JCO.2005.10.202. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767638 Clinical Trial.
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Richardson PG, et al. J Clin Oncol. 2006 Jul 1;24(19):3113-20. doi: 10.1200/JCO.2005.04.7779. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754936 Clinical Trial.
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC. Richardson PG, et al. Among authors: schuster mw. Br J Haematol. 2007 Jun;137(5):429-35. doi: 10.1111/j.1365-2141.2007.06585.x. Epub 2007 Apr 19. Br J Haematol. 2007. PMID: 17451408 Free article. Clinical Trial.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Richardson PG, et al. Blood. 2007 Nov 15;110(10):3557-60. doi: 10.1182/blood-2006-08-036947. Epub 2007 Aug 9. Blood. 2007. PMID: 17690257 Free article. Clinical Trial.
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC. San-Miguel JF, et al. Among authors: schuster mw. Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200040 Clinical Trial.
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J. Niesvizky R, et al. Among authors: schuster mw. Br J Haematol. 2008 Oct;143(1):46-53. doi: 10.1111/j.1365-2141.2008.07303.x. Epub 2008 Jul 31. Br J Haematol. 2008. PMID: 18673366 Free article.
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Chanan-Khan A, et al. Among authors: schuster mw. J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711175 Clinical Trial.
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL. Lonial S, et al. Among authors: schuster mw. Br J Haematol. 2008 Oct;143(2):222-9. doi: 10.1111/j.1365-2141.2008.07321.x. Epub 2008 Aug 18. Br J Haematol. 2008. PMID: 18713253 Free article.
84 results